高级检索
当前位置: 首页 > 详情页

Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China [2]Department of Endocrinology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China [3]The First People’s Hospital of Kashgar Prefecture, Kashgar, Xinjiang Uygur Autonomous Region, China [4]The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, China [5]Jiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogen Biology and Immunology, Xuzhou Medical University, Xuzhou, China [6]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China [7]Department of Science and Education, Guangzhou Hospital of Traditional Chinese Medicine, Guangzhou, China [8]Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China [9]Department of Ophthalmology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China [10]Department of Acupuncture-rehabilitation, Guangzhou-Liwan Hospital of Chinese Medicine, Guangzhou, China [11]Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China
出处:
ISSN:

关键词: Cassia mimosoides Linn Emodin Non-alcoholic fatty liver Farnesoid X receptor High fat diet Lipid and glucose metabolism

摘要:
Background: Cassia mimosoides Linn (CMD) is a traditional Chinese herb that clears liver heat and dampness. It has been widely administered in clinical practice to treat jaundice associated with damp-heat pathogen and obesity. Emodin (EMO) is a major bioactive constituent of CMD that has apparent therapeutic efficacy against obesity and fatty liver. Here, we investigated the protective effects and underlying mechanisms of EMO against high-fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD). Objective: We aimed to investigate whether EMO activates farnesoid X receptor (FXR) signaling to alleviate HFDinduced NAFLD. Materials and methods: In vivo assays included serum biochemical indices tests, histopathology, western blotting, and qRT-PCR to evaluate the effects of EMO on glucose and lipid metabolism disorders in wild type (WT) and FXR knockout mice maintained on an HFD. In vitro experiments included intracellular triglyceride (TG) level measurement and Oil Red O staining to assess the capacity of EMO to remove lipids induced by oleic acid and palmitic acid in WT and FXR knockout mouse primary hepatocytes (MPHs). We also detected mRNA expression of FXR signaling genes in MPHs. Results: After HFD administration, body weight and serum lipid and inflammation levels were dramatically increased in the WT mice. The animals also presented with impaired glucose tolerance, insulin resistance, and antioxidant capacity, liver tissue attenuation, and pathological injury. EMO remarkably reversed the foregoing changes in HFD-induced mice. EMO improved HFD-induced lipid accumulation, insulin resistance, inflammation, and oxidative stress in a dose-dependent manner in WT mice by inhibiting FXR expression. EMO also significantly repressed TG hyperaccumulation by upregulating FXR expression in MPHs. However, it did not improve lipid accumulation, insulin sensitivity, or glucose tolerance in HFD-fed FXR knockout mice. Conclusions: The present study demonstrated that EMO alleviates HFD-induced NAFLD by activating FXR signaling which improves lipid accumulation, insulin resistance, inflammation, and oxidative stress.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 3 区 医学
小类 | 2 区 全科医学与补充医学 2 区 植物科学 3 区 药物化学 3 区 药学
最新[2025]版:
大类 | 2 区 医学
小类 | 1 区 全科医学与补充医学 1 区 药学 2 区 药物化学 2 区 植物科学
JCR分区:
出版当年[2019]版:
Q1 PLANT SCIENCES Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Q2 PHARMACOLOGY & PHARMACY Q2 CHEMISTRY, MEDICINAL
最新[2023]版:
Q1 CHEMISTRY, MEDICINAL Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE Q1 PHARMACOLOGY & PHARMACY Q1 PLANT SCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China [2]Department of Endocrinology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China [3]The First People’s Hospital of Kashgar Prefecture, Kashgar, Xinjiang Uygur Autonomous Region, China [4]The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2020 今日访问量:0 总访问量:646 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号